Skip to main content
Clinical Trials/NCT01252849
NCT01252849CompletedNot Applicable

A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents

Glaukos Corporation1 site in 1 country119 target enrollmentStarted: December 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
119
Locations
1
Primary Endpoint
Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline

Study Overview

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Diagnosed with primary open-angle glaucoma (POAG)
  • •Subject on two topical hypotensive medications

Exclusion Criteria

  • •Traumatic, uveitic, neovascular, or angle closure glaucoma
  • •Fellow eye already enrolled

Arms & Interventions

First Arm: One iStent, medication

Experimental

Device: One iStent, medication

Intervention: iStent (Device)

Second Arm: Two iStents, medication

Experimental

Device: Two iStent devices, medication

Intervention: iStent (Device)

Third Arm: Three iStents, medication

Experimental

Device: Three iStent devices, medication

Intervention: iStent (Device)

Outcomes

Primary Outcomes

Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline

Time Frame: 12 Months

Secondary Outcomes

  • Mean diurnal IOP <18 mmHg at month 12(12 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials